KRP-109

• Description :

  KRP-109 is a neutrophil elastase (NE) inhibitor with activity in reducing lung inflammation. KRP-109 improves survival in mouse models and reduces the number of neutrophils and inflammation in the alveolar walls. KRP-109 significantly reduced cell and neutrophil counts in bronchoalveolar lavage fluid, as well as cytokine levels such as interleukin 1β and macrophage inflammatory protein 2. KRP-109 can be used in the research of severe pneumonia[1].

• CAS Number :

  [1275996-50-3]

• UNSPSC :

  12352005

• Target :

  Endogenous Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/krp-109.html

• Smiles :

  OC(/C=C\C(O)=O)=O.CCC1=C2C(N=C(C3=C(N4C[C@H](CC4)N(C)C)N=CC=C3)OC2=O)=CC(OC)=C1

• Molecular Formula :

  C26H30N4O7

• Molecular Weight :

  510.54

• References & Citations :

  [1]In vivo efficacy of KRP-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported